A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells
Semaglutide slows down the rate at which your stomach sends foods to your large intestine, which results in a longer feeling of fullness
It can even fix fatty liver disease
SELECT Trials Groundbreaking Results In 2023, in a landmark finding, the SELECT trial showed that adults with overweight or obesity but without diabetes, who had previously experienced a heart attack, stroke and/or had peripheral artery disease, taking semaglutide had a 20% reduction in major adverse cardiac events such as heart attacks and strokes compared to those on placebo over the course of 3 years
DNAMAN software was used to perform multiple alignments
For routine dosing, this loss is negligible